Clinical trials
Phase 3 Coronavirus Infections trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
122 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 77 |
| 2021 | 26 |
| 2022 | 9 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 68 |
| Terminated | 20 |
| Unknown status | 19 |
| Recruiting | 7 |
| Withdrawn | 7 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 10 |
| BioNTech SE | 7 |
| ModernaTX, Inc. | 5 |
| Novavax | 4 |
| CureVac | 3 |
| Azienda Ospedaliera Universitaria Integrata Verona | 2 |
| Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products | 2 |
| Eli Lilly and Company | 2 |
| Northwell Health | 2 |
| Novartis Pharmaceuticals | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Coronavirus Infections | 122 |
| COVID-19 | 102 |
| Severe Acute Respiratory Syndrome | 28 |
| Virus Diseases | 24 |
| Coronaviridae Infections | 16 |
| RNA Virus Infections | 16 |
| Nidovirales Infections | 14 |
| Pneumonia | 11 |
| Respiratory Distress Syndrome | 9 |
| Pneumonia, Viral | 8 |
Trials
Showing 26 to 50 of 122. Each trial links to its page on Pharma Observatory.
22 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.